The Role of Context in Integrating Buprenorphine into a Drop-In Center in Kampala, Uganda, Using the Consolidated Framework for Implementation Research.
Africa
Uganda
buprenorphine
opioid use disorder
people who use opioids
syringe service programs
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
20 08 2022
20 08 2022
Historique:
received:
29
06
2022
revised:
02
08
2022
accepted:
18
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Although Africa has long borne the brunt of the human immunodeficiency virus (HIV) epidemic, until recently, the continent has been considered largely free of illicit drug use and injection drug use in particular. In Uganda, the number of people who use or inject drugs (PWUD and PWID, respectively) has increased, and PWID are a key population at high risk for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. However, harm reduction practices, including providing clean injection equipment and medication-assisted treatment (MAT), have only recently been piloted in the country. This project aims to integrate buprenorphine into a harm reduction drop-in center (DIC). The Consolidated Framework for Implementation Research was used to guide our preparations to integrate buprenorphine into existing practices at a harm reduction DIC. We conducted key informant interviews with members of a community advisory board and DIC staff to document this process, its successes, and its failures. Results indicate that criminalization of drug use and stigmatization of PWUD challenged efforts to provide buprenorphine treatment in less regulated community settings. DIC staff and their commitment to harm reduction and advocacy facilitated the process of obtaining necessary approvals.
Sections du résumé
BACKGROUND
Although Africa has long borne the brunt of the human immunodeficiency virus (HIV) epidemic, until recently, the continent has been considered largely free of illicit drug use and injection drug use in particular. In Uganda, the number of people who use or inject drugs (PWUD and PWID, respectively) has increased, and PWID are a key population at high risk for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. However, harm reduction practices, including providing clean injection equipment and medication-assisted treatment (MAT), have only recently been piloted in the country. This project aims to integrate buprenorphine into a harm reduction drop-in center (DIC).
METHODS
The Consolidated Framework for Implementation Research was used to guide our preparations to integrate buprenorphine into existing practices at a harm reduction DIC. We conducted key informant interviews with members of a community advisory board and DIC staff to document this process, its successes, and its failures.
RESULTS
Results indicate that criminalization of drug use and stigmatization of PWUD challenged efforts to provide buprenorphine treatment in less regulated community settings.
CONCLUSIONS
DIC staff and their commitment to harm reduction and advocacy facilitated the process of obtaining necessary approvals.
Identifiants
pubmed: 36012015
pii: ijerph191610382
doi: 10.3390/ijerph191610382
pmc: PMC9407835
pii:
doi:
Substances chimiques
Buprenorphine
40D3SCR4GZ
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDA NIH HHS
ID : R34 DA052178
Pays : United States
Références
Int J Drug Policy. 2021 Jan;87:102990
pubmed: 33099159
Int J Drug Policy. 2016 Jan;27:132-7
pubmed: 26342275
Subst Abus. 2020;41(3):356-364
pubmed: 31403907
Curr Opin HIV AIDS. 2012 Jul;7(4):320-5
pubmed: 22498479
Health Promot Chronic Dis Prev Can. 2018 Jun;38(6):234-243
pubmed: 29911819
PLoS One. 2020 Apr 22;15(4):e0231969
pubmed: 32320448
Implement Sci. 2017 Feb 10;12(1):15
pubmed: 28187747
Int J Drug Policy. 2016 Apr;30:74-81
pubmed: 27017376
Bull World Health Organ. 2004 Sep;82(9):641
pubmed: 15628199
Subst Abuse Treat Prev Policy. 2016 Sep 01;11(1):31
pubmed: 27586507
Curr Opin Psychiatry. 2008 May;21(3):229-33
pubmed: 18382219
Lancet HIV. 2019 Feb;6(2):e128-e136
pubmed: 30558843
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
PLoS Med. 2011 Nov;8(11):e1001122
pubmed: 22110406
AIDS Care. 2017 Sep;29(9):1119-1128
pubmed: 28281354
Lancet. 2010 Jul 24;376(9737):285-301
pubmed: 20650522
Lancet. 2007 Oct 6;370(9594):1241-52
pubmed: 17804059
Curr Psychiatry Rep. 2019 Feb 7;21(2):10
pubmed: 30729322
Lancet. 2011 Oct 22;378(9801):1441-2
pubmed: 22008422
JAMA Netw Open. 2020 Feb 5;3(2):e1920622
pubmed: 32022884
Int J Drug Policy. 2021 May;91:103180
pubmed: 33640213
AIDS Care. 2013;25(11):1370-4
pubmed: 23406479
J Addict Dis. 2012;31(3):278-87
pubmed: 22873189
Subst Use Misuse. 2017 May 12;52(6):773-784
pubmed: 28379107
Curr Opin HIV AIDS. 2019 Sep;14(5):409-414
pubmed: 31219890
AIDS Care. 2004 May;16(4):426-33
pubmed: 15203411
J Addict Med. 2019 Jul/Aug;13(4):264-271
pubmed: 30585875
AIDS Care. 2010 Nov;22(11):1305-13
pubmed: 20640954
AIDS Patient Care STDS. 2014 Feb;28(2):71-81
pubmed: 24428768
Addict Sci Clin Pract. 2017 Oct 18;12(1):23
pubmed: 29041950
Int J Drug Policy. 2014 Jan;25(1):53-60
pubmed: 24113623
J Addict Med. 2015 Mar-Apr;9(2):163-4
pubmed: 25807454
Harm Reduct J. 2022 Jul 10;19(1):75
pubmed: 35818071
J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S46-53
pubmed: 21317594
Health Justice. 2020 Apr 29;8(1):9
pubmed: 32350636
Soc Sci Med. 2019 Jul;232:324-331
pubmed: 31125801
J Gen Intern Med. 2020 Dec;35(Suppl 3):954-963
pubmed: 33145687
Harm Reduct J. 2019 Sep 3;16(1):56
pubmed: 31481086
J Addict Med. 2022 Jul-Aug 01;16(4):447-453
pubmed: 34775441
Drug Alcohol Rev. 2010 Jul;29(4):437-45
pubmed: 20636661
Harm Reduct J. 2005 Aug 25;2:12
pubmed: 16122382
Lancet. 2013 Nov 9;382(9904):1564-74
pubmed: 23993281
Subst Abuse. 2022 Jun 27;16:11782218221103859
pubmed: 35783464
BMC Fam Pract. 2019 Nov 15;20(1):157
pubmed: 31729957
Subst Abuse Treat Prev Policy. 2022 Jul 15;17(1):51
pubmed: 35841036
Psychol Addict Behav. 2011 Jun;25(2):262-8
pubmed: 21668086
Subst Abus. 2018;39(2):167-172
pubmed: 29474119
Cochrane Database Syst Rev. 2014 Feb 06;(2):CD002207
pubmed: 24500948
Hum Psychopharmacol. 2012 May;27(3):338-41
pubmed: 22585594
J Subst Abuse Treat. 2020 Dec;119:108146
pubmed: 33138929
Lancet. 2007 Apr 21;369(9570):1323-1325
pubmed: 17448801
Harm Reduct J. 2017 May 12;14(1):23
pubmed: 28499432
Int J Drug Policy. 2018 Jun;56:162-175
pubmed: 29731288
Lancet. 2010 Jul 24;376(9737):268-84
pubmed: 20650523
J Addict Med. 2010 Dec;4(4):204-10
pubmed: 21170143
Int J Environ Res Public Health. 2019 Feb 28;16(5):
pubmed: 30823440
Int J Drug Policy. 2016 Apr;30:59-65
pubmed: 26831364
Int J Drug Policy. 2017 Jan;39:1-13
pubmed: 27770693
Lancet. 2019 Oct 26;394(10208):1560-1579
pubmed: 31657732
Int J Drug Policy. 2016 Apr;30:99-106
pubmed: 26614737
Int J Psychiatry Med. 2021 Jan;56(1):14-39
pubmed: 32726568
Public Health Rep. 2002;117 Suppl 1:S135-45
pubmed: 12435837